

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**2024 THIRD QUARTERLY REPORT**

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively “**We**” or “**Our**”) for financial year 2024 (the “**2024 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, October 28, 2024

*As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.*

\* For identification purpose only

## I. Important Notice

- 1.1 The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2024 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2024 Third Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ming Shi, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2024 Third Quarterly Report.
- 1.3 The 2024 Third Quarterly Report of the Company has not been audited.
- 1.4 Definitions

### Definitions of frequently-used terms

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“BLA”	biologics license application
“Board”	the board of Directors of the Company
“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report and for geographical reference only, excludes the Hong Kong Special Administrative Region of the PRC, the Macao Special Administrative Region of the PRC and Taiwan
“CDMO”	Contract Development and Manufacturing Organization, a CMO that in addition to comprehensive drug manufacturing services, also provides process development, formulation development, clinical trial medications, production of chemically or biologically synthesized active pharmaceutical ingredients, intermediate manufacturing, formulation production (such as powders and injectables), and packaging, as well as customized research and development services for related products

“CRDMO”	Contract Research Development and Manufacturing Organization
“CRO”	Contract Research Organization, an academic or commercial scientific institution that provides specialized services to pharmaceutical companies and research institutions during the drug development process through contractual agreements
“CTDMO”	Contract Testing Development and Manufacturing Organization
“Director(s)”	the director(s) of the Company or any one of them
“end of the Reporting Period”	September 30, 2024
“GLP”	good laboratory practice
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on The Stock Exchange of Hong Kong Limited
“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“IND”	investigational new drug
“Reporting Period”	the period from July 1, 2024 to September 30, 2024
“RMB” or “RMB million”	Renminbi yuan or million yuan
“R&D”	research and development
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“Supervisory Committee”	the supervisory committee of the Company
“SMO”	Site Management Organization
“WuXi ATU”	CTDMO business of the Company

“WuXi Biology”	biology business of the Company
“WuXi Chemistry”	chemistry business of the Company
“WuXi DDSU”	domestic new drug discovery service unit of the Company
“WuXi Testing”	testing business of the Company

## **II. Company Profile**

As a global company with operations across Asia, Europe, and North America, we provide a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, our integrated, end-to-end services include chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, and advanced therapies CTDMO, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

The Company has always adhered to the highest international quality control standards. Since its establishment, the Company has earned a well-recognized reputation for excellent service records and a comprehensive intellectual property protection system in the global pharmaceutical research and development industry. The service data developed by the Company is highly recognized and trusted within the industry. The Company continuously optimizes and explores business synergies across sectors to better serve global clients, further strengthens its unique integrated CRDMO and CTDMO business models, and provides one-stop services to meet clients’ needs from discovery to development and manufacturing.

### III. Major financial data

#### 1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period	Year-over-year increase/decrease (%)	From the beginning	Year-over-year increase/decrease (%)
			of the year to the end of the Reporting Period	
Revenue	10,461,083,991.74	-1.96	27,702,002,254.76	-6.23
Net profit attributable to the owners of the Company	2,293,112,685.17	-17.02	6,532,934,698.28	-19.11
Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items	2,267,805,125.46	-23.76	6,681,732,283.44	-14.22
Net cash flows from operating activities	Not applicable	Not applicable	8,379,092,385.15	-18.78
Basic earnings per share (RMB/share)	0.80	-14.89	2.25	-18.18
Diluted earnings per share (RMB/share)	0.79	-15.96	2.24	-17.95
Weighted average return on net assets (%)	4.12	Decreased by 1.47 percentage points	11.73	Decreased by 4.46 percentage points
				<b>Increase/decrease as at the end of the Reporting Period as compared to the end of the previous year (%)</b>
	<b>As at the end of the Reporting Period</b>	<b>As at the end of the previous year</b>		
Total assets	74,238,239,875.23	73,669,349,307.12		0.77
Equity attributable to the owners of the Company	55,173,547,660.38	55,122,453,910.73		0.09

*Note:* Net profit attributable to the owners of the Company after deducting non-recurring gain or loss items is prepared according to the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss” amended in 2023. Among them, government grants that are closely related to the Company’s normal business operations, in compliance with policy regulations, and have a continuous impact on the Company’s profit or loss according to established standards are not included in the non-recurring gain or loss items. The data during the comparison period has been adjusted accordingly.

## 2. Non-recurring gain or loss items and amounts

Applicable    Not applicable

Unit: RMB

Non-recurring gain or loss item	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets, including the write-off portion of asset impairment provisions that have been made	-5,465,713.65	-11,555,573.37	
Government grants included in profit or loss of the current period, except for those that are closely related to the Company's normal business operations, in compliance with policy regulations, and have a continuous impact on the Company's profit or loss according to established standards	58,760,632.28	188,411,104.79	
Gain or loss arising from changes in fair value of financial assets and financial liabilities held by a non-financial enterprise, and gain or loss arising from disposal of financial assets and financial liabilities, except effective hedging business related to the Company's normal operations.	-1,098,036.63	-310,606,580.68	It was mainly due to changes in fair value and gains and losses on disposal of non-current financial assets and derivative financial instruments.
Other non-operating income and expenses other than the above items	-6,708,495.94	-32,980,743.50	
Less: Effect of income tax	19,867,605.03	-15,833,087.52	
Impact on non-controlling interests (after tax)	313,221.32	-2,101,120.08	
Total	<u>25,307,559.71</u>	<u>-148,797,585.16</u>	

Reasons should be provided for identifying items not listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss” as non-recurring gain or loss items with significant amounts, as well as for classifying the non-recurring gain or loss items listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Gain or Loss” as recurring gain or loss items.

Applicable    Not applicable

### 3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

✓ Applicable     Not applicable

Item	Change (%)	Main reasons
Revenue for the period from the beginning of the year to the end of the Reporting Period	-6.23	Please refer to the analysis below for details

Unit: Ten thousand RMB

Operating segments	First three quarters of 2024	First three quarters of 2023	Change (%)
WuXi Chemistry	2,009,380.97	2,124,138.51	-5.40
WuXi Testing	461,832.02	485,424.43	-4.86
WuXi Biology	182,594.01	189,491.26	-3.64
WuXi ATU	85,303.65	102,825.47	-17.04
WuXi DDSU	28,970.17	49,110.01	-41.01
Others	2,119.40	3,142.94	-32.57
Total	<u>2,770,200.23</u>	<u>2,954,132.61</u>	<u>-6.23</u>

*Note:* Any discrepancies between the total shown and the sum of the amounts listed in the above table and the following paragraphs are due to rounding.

In the first three quarters of 2024, we added over 800 new customers while maintaining the existing base of over 6,000 active customers. Demand from customers across regions continued to grow. As of September 30, 2024, backlog achieved RMB43.82 billion, growing 35.2% year-over-year. In the first three quarters of 2024:

- Revenue from the top 20 global pharmaceutical companies reached RMB11.22 billion, growing 23.1% year-over-year excluding COVID-19 commercial projects.
- Revenue from US-based customers was RMB17.62 billion, excluding COVID-19 commercial projects, revenue increased 7.6% year-over-year; revenue from Europe-based customers increased 14.8% year-over-year to RMB3.53 billion; revenue from China-based customers decreased 3.9% year-over-year to RMB5.16 billion; and revenue from customers in other regions decreased 16.5% year-over-year to RMB1.40 billion.

In the first three quarters of 2024, revenue of the Company was RMB27.70 billion, excluding COVID-19 commercial projects, revenue grew 4.6% year-over-year, due primarily to the following:

**(1) WuXi Chemistry**

Despite external challenges, Q3 revenue of WuXi Chemistry grew 1.4% year-over-year to RMB7.88 billion; excluding COVID-19 commercial projects, revenue increased 26.4% year-over-year. Revenue reached RMB20.09 billion in the first three quarters of 2024, growing 10.4% year-over-year excluding COVID-19 commercial projects. In the first three quarters of 2024:

- Small molecule drug discovery services (“**R**”) continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 450,000 new compounds to customers, which resulted in 7% year-over-year growth. Through our “follow-the-customer” and “follow-the-molecule” strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business. The number of molecules converted from R to D&M continued to grow.
- Small molecule development and manufacturing (“**D**”&“**M**”) services remains strong. Revenue of small molecule D&M services reached RMB12.47 billion, up 7.0% year-over-year excluding COVID-19 commercial projects. The small molecule CDMO pipeline continued to expand. In the first three quarters of 2024, 915 new molecules were added to the small molecule D&M pipeline. As of September 30, 2024, our small molecule D&M pipeline reached 3,356 molecules, including 68 commercial projects, 79 in phase III, 357 in phase II and 2,852 in phase I and pre-clinical stages, among which 20 commercial and phase III projects were added in the first three quarters of 2024. In May 2024, we announced the groundbreaking of the new R&D and manufacturing site in Singapore; Phase I is expected to commence operation in 2027.
- TIDES business (mainly oligo and peptides) sustains rapid growth. Revenue of TIDES grew strongly by 71.0% year-over-year to RMB3.55 billion in the first three quarters of 2024. TIDES full-year revenue is expected to grow over 60%. As of September 30, 2024, TIDES backlog grew 196% year-over-year. TIDES D&M customers grew 20% year-over-year, and the number of TIDES molecules grew 22% year-over-year. In January 2024, the total reactor volume of solid phase peptide synthesizers increased to 32,000L, and is expected to reach 41,000L by the end of 2024; it will continue to increase in 2025.



## (2) *WuXi Testing*

Revenue of WuXi Testing reached RMB4.62 billion. In the first three quarters of 2024:

- Revenue of lab testing services was down 7.9% year-over-year to RMB3.26 billion, with Q3 revenue up 5.5% quarter-over-quarter. Among which, revenue from drug safety evaluation services was down 10.1% year-over-year in the first three quarters of 2024 due to market impact as pricing gradually reflected in revenue along with backlog conversion, while Q3 revenue up 10.1% quarter-over-quarter, maintaining an industry leading position in the Asia-Pacific region. In the first three quarters of 2024, the Qidong and Chengdu facilities received the National Medical Products Administration (NMPA) and Organization for Economic Co-operation and Development (OECD) GLP qualifications. The Suzhou facility was reviewed for the first time by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for on-site audit and successfully passed. New modality business continued to develop, while new vaccine capability continued to improve, and market share of nucleic acids, conjugates, and mRNA further expanded. The Company is committed to actively enabling customers going global, and supported over 70% China biotech companies with successful out-licensing deals in the first three quarters of 2024.
- Revenue of clinical CRO & SMO grew 3.4% year-over-year to RMB1.36 billion. Among which, SMO revenue grew 16.0% year-over-year, maintaining industry leading position in China. In the first three quarters of 2024, clinical CRO enabled our customers to obtain 21 IND approvals and SMO supported 50 new drug approvals for customers. The SMO business continued steady growth, maintaining significant advantages in multiple therapeutic areas (cardiovascular disease, ophthalmology, rheumatology, central nervous system, endocrinology, medical aesthetics and rare tumors, etc.).

### **(3) *WuXi Biology***

Revenue of WuXi Biology reached RMB1.83 billion. In the first three quarters of 2024:

- The Company focused on improving capabilities related to new modalities. Revenue from new modalities grew 6.0% year-over-year, contributing 28.5% of WuXi Biology revenue. The number of customers and projects served by the nucleic acid platform continued to increase. Cumulatively, the Company provided services to over 280 customers, and successfully delivered over 1,300 projects since 2021. The Company proactively built capabilities to collaboratively develop membrane proteins and peptides, leading to a remarkable increase in business volume of related protein production, screening and subsequent validation services.
- The Company further integrated resources of the in vivo pharmacology platform, and continued to improve platform capabilities and efficiency. The Company also fully leveraged the advantage of the one-stop service platform with in vitro & in vivo synergy to further gain market share in metabolic, cardiovascular and neurological areas, and the number of customers served grew over 50% year-over-year. The Company continued to build a comprehensive and integrated screening platform, with related revenue up 20.2% year-over-year, among which revenue from peptide discovery services grew over 200% year-over-year.
- In the first three quarters of 2024, WuXi Biology continued to generate downstream opportunities and contributed over 20% of the Company's new customers.

### **(4) *WuXi ATU***

Revenue of WuXi ATU reached RMB0.85 billion. In the first three quarters of 2024:

- 1) commercial projects still in the early stages of ramping up; 2) certain projects were delayed, or cancelled due to customers' considerations; and 3) insufficient new business wins due to the proposed U.S. legislation.

- The Company continues to improve our CTDMO integrated enabling platform. As of September 30, 2024, we provided development, testing and manufacturing services for 59 projects, including 2 commercial projects, 4 Phase III projects (1 project in BLA preparation stage), 8 Phase II projects and 45 pre-clinical and Phase I projects, among which, the world’s first innovative TIL-based therapy was approved by the U.S. Food and Drug Administration (FDA) in February 2024. We are preparing for BLA filing to manufacture the lentiviral vector (LVV) used in a commercial CAR-T product. We completed process performance qualification (PPQ), started post-PPQ manufacturing, and expect to file pre-approval submission (PAS) to FDA in the fourth quarter of 2024. Moreover, we enabled the world’s first clinical trial of in vivo CAR-T therapy, providing end-to-end services of process development and GMP manufacturing for plasmids and viral vectors.

#### **IV. Information about shareholders**

##### **1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period**

	Unit: Share
Total number of ordinary shareholders as at the end of the Reporting Period	385,041
Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	0

**Shareholdings of top 10 Shareholders  
(excluding shares borrowed from financial institution backed securities)**

Full name of shareholders	Nature of shareholders	Number of		Number of Shares subject to trading restrictions	Pledged, marked or frozen Status	Shares Number
		Shares held	Percentage (%)			
HKSCC NOMINEES LIMITED <sup>(Note 1)</sup>	Overseas legal entity	387,025,502	13.2910	0	Unknown	0
Hong Kong Securities Clearing Company Limited <sup>(Note 2)</sup>	Overseas legal entity	143,295,973	4.9210	0	Nil	0
G&C VI Limited	Overseas legal entity	143,015,795	4.9114	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	104,626,051	3.5930	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) (北京中民銀孚投資 管理有限公司 — 嘉興宇祥投資合夥企業 (有限合夥))	Other	87,074,568	2.9903	0	Nil	0
G&C V Limited	Overseas legal entity	73,105,843	2.5106	0	Nil	0
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療 健康混合型證券投資基金)	Other	63,865,186	2.1932	0	Nil	0
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	Overseas legal entity	60,597,907	2.0810	0	Nil	0
Bank of China Co., Ltd. — Huabao CSI Medical Service Exchange-traded Open- end Index Securities Investment Fund (中國 銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資 基金)	Other	57,123,648	1.9617	0	Nil	0
Industrial and Commercial Bank of China — SSE 50 Exchange-traded Open-end Index Securities Investment Funds (中國工商銀行 — 上證50交易型 開放式指數證券投資基金)	Other	49,970,522	1.7161	0	Nil	0

**Shareholdings of top 10 holders of Shares not subject to trading restrictions  
(excluding shares borrowed from financial institution backed securities)**

Full name of shareholders	Number of Shares not subject to trading restrictions	Class and number of Shares	
		Class	Number
HKSCC NOMINEES LIMITED <sup>(Note 1)</sup>	387,025,502	Overseas-listed foreign shares	387,025,502
Hong Kong Securities Clearing Company Limited <sup>(Note 2)</sup>	143,295,973	RMB-denominated ordinary shares	143,295,973
G&C VI Limited	143,015,795	RMB-denominated ordinary shares	143,015,795
G&C IV Hong Kong Limited	104,626,051	RMB-denominated ordinary shares	104,626,051
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (北京中民銀孚投資管理有限公司 — 嘉興宇祥 投資合夥企業(有限合夥))	87,074,568	RMB-denominated ordinary shares	87,074,568
G&C V Limited	73,105,843	RMB-denominated ordinary shares	73,105,843
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	63,865,186	RMB-denominated ordinary shares	63,865,186
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	60,597,907	RMB-denominated ordinary shares	60,597,907
Bank of China Co., Ltd. — Huabao CSI Medical Service Exchange-traded Open-end Index Securities Investment Fund (中國銀行股份有限公司 — 華寶中 證醫療交易型開放式指數證券投資基金)	57,123,648	RMB-denominated ordinary shares	57,123,648
Industrial and Commercial Bank of China — SSE 50 Exchange-traded Open-end Index Securities Investment Funds (中國工商銀行 — 上證50交易型 開放式指數證券投資基金)	49,970,522	RMB-denominated ordinary shares	49,970,522
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited and Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership) being part of the top 10 shareholders of the Company, are acting in concert.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

*Note 1:* HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

*Note 2:* Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

**2. Participation of shareholders holding 5% or more of the shares, top 10 shareholders and top 10 holders of shares not subject to trading restrictions in the borrowing of shares from financial institution backed securities**

✓ Applicable     Not applicable

Unit: Share

**Participation of shareholders holding 5% or more of the shares, top 10 shareholders and top 10 holders of shares not subject to trading restrictions in the borrowing of shares from financial institution backed securities**

Name of Shareholder (full name)	Shares held in ordinary accounts and credit accounts at the beginning of the period		Shares borrowed from financial institution backed securities and not yet returned at the beginning of the period		Shares held in ordinary accounts and credit accounts at the end of the period		Shares borrowed from financial institution backed securities and not yet returned at the end of the period	
	Number in aggregate	Proportion (%) (note 1)	Number in aggregate	Proportion (%) (note 1)	Number in aggregate	Proportion (%) (note 2)	Number in aggregate	Proportion (%) (note 2)
	Bank of China Co., Ltd. — Huabao CSI Medical Service Exchange-traded Open-end Index Securities Investment Fund (中國銀行股份有限公司 — 華寶中證醫療交易型開放式指數證券投資基金)	34,801,978	1.1722	153,100	0.0052	57,123,648	1.9617	0
Industrial and Commercial Bank of China — SSE 50 Exchange-traded Open-end Index Securities Investment Funds (中國工商銀行 — 上證50交易型開放式指數證券投資基金)	25,002,381	0.8422	196,000	0.0066	49,970,522	1.7161	0	0.0000

*Note 1:* The proportion of shares held in ordinary accounts and credit accounts at the beginning of the period and the proportion of shares borrowed from financial institution backed securities and not yet returned at the beginning of the period are calculated based on the total share capital of the Company at the beginning of the period.

*Note 2:* The proportion of shares held in ordinary accounts and credit accounts at the end of the period and the proportion of shares borrowed from financial institution backed securities and not yet returned at the end of the period are calculated based on the total share capital of the Company at the end of the period.

**3. Changes of top 10 shareholders and top 10 holders of shares not subject to trading restrictions as compared with the previous period arising from borrowing/return of shares from financial institution backed securities**

Applicable    ✓ Not applicable

**V. Other reminders**

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to

Applicable    ✓ Not applicable

**VI. Quarterly financial statements**

**1. Type of auditor's opinion**

Applicable    ✓ Not applicable

## 2. Financial statements

### Consolidated Balance Sheet

As at September 30, 2024

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB    Type of audit: Unaudited

Item	As at September 30, 2024	As at December 31, 2023
<b>Current Assets:</b>		
Bank balances and cash	14,051,541,214.47	13,764,058,665.13
Financial assets held for trading	—	11,003,188.04
Derivative financial assets	100,894,684.14	414,035,113.41
Note receivables	98,674,289.85	20,196,868.46
Trade receivables	8,014,543,781.69	7,901,380,298.53
Prepayments	238,754,273.51	243,663,367.83
Other receivables	305,029,806.15	168,176,303.89
Including: Interest receivables	176,776,121.11	10,174,736.26
Dividend receivables	—	—
Inventories	5,347,792,758.02	4,736,229,956.28
Contract assets	1,135,031,691.43	1,234,393,855.26
Non-current assets due within one year	—	785,779,534.14
Other current assets	1,170,486,377.86	1,143,553,809.85
Total Current Assets	30,462,748,877.12	30,422,470,960.82
<b>Non-current Assets:</b>		
Long-term equity investments	2,370,173,557.65	2,215,629,616.25
Other non-current financial assets	8,660,659,670.20	8,626,009,050.68
Fixed assets	18,342,952,353.55	17,189,915,307.85
Construction in progress	6,026,413,201.93	6,982,392,940.58
Productive biological assets	1,096,719,000.00	1,012,478,000.00
Right-of-use assets	1,491,572,314.82	1,391,213,425.45
Intangible assets	1,793,353,509.96	1,863,800,704.15
Goodwill	1,836,575,496.99	1,820,872,684.75
Long-term deferred expenditures	1,646,432,316.09	1,679,721,310.08
Deferred tax assets	402,915,003.64	366,691,216.70
Other non-current assets	107,724,573.28	98,154,089.81
Total Non-current Assets	43,775,490,998.11	43,246,878,346.30
Total Assets	74,238,239,875.23	73,669,349,307.12



Item	As at September 30, 2024	As at December 31, 2023
<b>Current Liabilities:</b>		
Short-term borrowings	2,704,989,653.78	3,667,059,680.42
Derivative financial liabilities	64,242,595.44	501,871,397.56
Trade payables	1,998,329,644.58	1,645,321,546.91
Contract liabilities	2,471,385,961.82	1,955,363,182.24
Payroll payables	1,611,274,803.01	2,125,635,919.87
Tax payables	950,547,330.94	1,373,741,119.25
Other payables	2,855,245,818.77	3,192,265,947.14
Including: Interest payables	27,969,705.30	22,292,809.61
Dividend payables	—	—
Non-current liabilities due within one year	271,405,290.68	295,037,372.18
Total Current Liabilities	12,927,421,099.02	14,756,296,165.57
<b>Non-current Liabilities:</b>		
Long-term borrowings	2,911,138,289.87	687,016,640.84
Lease liabilities	1,202,535,032.59	1,098,552,195.37
Deferred income	1,019,988,401.76	1,079,932,389.70
Deferred tax liabilities	593,914,950.00	530,106,502.90
Total Non-current Liabilities	5,727,576,674.22	3,395,607,728.81
Total Liabilities	18,654,997,773.24	18,151,903,894.38
<b>Owners' Equity (or Shareholders' Equity):</b>		
Paid-in capital (or share capital)	2,911,927,203.00	2,968,844,903.00
Capital reserve	25,575,508,845.13	28,401,011,161.70
Less: Treasury shares	3,870,742,317.26	3,156,528,928.12
Other comprehensive income	109,148,911.82	112,305,624.84
Special reserve	—	—
Surplus reserve	1,023,342,127.82	1,023,342,127.82
Undistributed profit	29,424,362,889.87	25,773,479,021.49
Total Equity (or Shareholders' Equity)		
attributable to owners of the Company	55,173,547,660.38	55,122,453,910.73
Non-controlling interests	409,694,441.61	394,991,502.01
Total Owners' Equity (or Shareholders' Equity)	55,583,242,101.99	55,517,445,412.74
Total Liabilities and Owners' Equity (or Shareholders' Equity)	74,238,239,875.23	73,669,349,307.12

Person in charge of the Company:

Ge Li

Chief Financial Officer:

Ming Shi

Director of the Accounting Department:

Jin Sun

## Consolidated Income Statement

January to September 2024

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB    Type of audit: Unaudited

Item	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
I. Total revenue	27,702,002,254.76	29,541,326,133.58
Including: Revenue	27,702,002,254.76	29,541,326,133.58
II. Total cost	19,967,164,047.62	20,390,754,912.94
Including: Cost	16,440,256,129.17	17,341,307,169.32
Taxes and surcharges	218,784,249.97	175,990,089.52
Selling expenses	546,582,318.74	521,220,394.83
Administrative expenses	1,869,468,114.84	1,979,875,643.41
Research and development expenses	954,042,826.94	1,025,811,070.87
Finance expenses	-61,969,592.04	-653,449,455.01
Including: Interest expense	150,222,876.33	113,947,206.59
Interest income	467,311,764.91	319,668,946.61
Add: Other income	287,254,161.42	286,536,806.88
Investment gains (“-” indicating loss)	-164,809,637.05	463,436,866.04
Including: Gains from investments in associates and joint ventures	198,950,236.95	-51,583,124.74
Gains from changes in fair value (“-” indicating loss)	217,646,546.11	102,676,079.72
Credit impairment losses (“-” indicating loss)	-155,999,892.45	-128,620,014.23
Assets impairment losses (“-” indicating loss)	-20,104,426.49	-61,486,509.43
Gains on assets disposal (“-” indicating loss)	-7,955,695.32	-5,697,972.07
III. Operating profit (“-” indicating loss)	7,890,869,263.36	9,807,416,477.55
Add: Non-operating income	5,586,936.32	6,624,331.87
Less: Non-operating expenses	42,160,110.47	32,074,532.76
IV. Total profit (“-” indicating total loss)	7,854,296,089.21	9,781,966,276.66
Less: Income tax expenses	1,252,684,573.24	1,633,319,192.33

Item	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
V. Net profit (“-” indicating net loss)	6,601,611,515.97	8,148,647,084.33
(I) Classified by continuity of operations		
1. Net profit from continuing operations (“-” indicating net loss)	6,601,611,515.97	8,148,647,084.33
2. Net profit from discontinued operations (“-” indicating net loss)	—	—
(II) Classified by ownership		
1. Net profit attributable to the owners of the Company (“-” indicating net loss)	6,532,934,698.28	8,076,407,160.91
2. Net profit attributable to non-controlling shareholders (“-” indicating net loss)	68,676,817.69	72,239,923.42
VI. Other comprehensive income, net of tax	-3,353,834.76	-543,935,758.12
(I) Other comprehensive income attributable to owners of the Company, net of tax	-3,156,713.02	-535,163,387.67
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-3,156,713.02	-535,163,387.67
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	157,680,974.11	-967,296,336.10
(6) Exchange difference on translation of foreign financial statements	-160,837,687.13	432,132,948.43
(7) Others	—	—

<b>Item</b>	<b>First three quarters of 2024 (January – September)</b>	<b>First three quarters of 2023 (January – September)</b>
(II) Other comprehensive income attributable to non-controlling shareholders, net of tax	-197,121.74	-8,772,370.45
VII. Total comprehensive income	6,598,257,681.21	7,604,711,326.21
(I) Total comprehensive income attributable to owners of the Company	6,529,777,985.26	7,541,243,773.24
(II) Total comprehensive income attributable to non-controlling shareholders	68,479,695.95	63,467,552.97
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	2.25	2.75
(II) Diluted earnings per share (RMB per share)	2.24	2.73

For the business combination involving enterprises under common control during the Reporting Period, realized net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Person in charge of the Company:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

## Consolidated Statement of Cash Flows

January to September 2024

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
<b>I. Cash flow from operating activities:</b>		
Cash received from sale of goods or rendering of services	29,359,129,012.71	29,156,882,495.54
Refunds of taxes and surcharges	1,312,328,095.05	1,335,873,478.10
Cash received relating to other operating activities	575,390,065.07	1,070,091,927.36
Sub-total of cash inflow from operating activities	31,246,847,172.83	31,562,847,901.00
Cash paid for purchasing goods and receiving services	10,928,215,498.32	9,995,805,548.50
Cash paid to and on behalf of employees	8,183,330,993.39	8,258,283,939.09
Payments of taxes and surcharges	2,369,175,464.68	1,728,708,555.73
Cash paid relating to other operating activities	1,387,032,831.29	1,263,261,998.11
Sub-total of cash outflow from operating activities	22,867,754,787.68	21,246,060,041.43
Net cash flow generated from operating activities	8,379,092,385.15	10,316,787,859.57
<b>II. Cash flow from investing activities:</b>		
Cash received from disposal of investments	5,266,733,483.82	1,444,052,430.09
Cash received from return on investments	242,713,508.52	101,907,253.66
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	9,734,408.38	11,071,989.61
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
Sub-total of cash inflow from investing activities	5,519,181,400.72	1,557,031,673.36
Cash paid to acquire fixed assets, intangible assets and other long-term assets	2,491,653,740.12	3,649,714,542.52
Cash paid to acquire investments	6,221,744,533.73	3,667,190,618.13
Net cash paid to acquire subsidiaries and other business entities	—	22,091,789.01
Cash paid relating to other investing activities	—	—
Sub-total of cash outflow from investing activities	8,713,398,273.85	7,338,996,949.66
Net cash flow from investing activities	-3,194,216,873.13	-5,781,965,276.30

Item	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
<b>III. Cash flow from financing activities:</b>		
Cash received from capital contributions	16,427,943.88	58,303,918.84
Including: Cash received from capital contribution by non-controlling shareholders of subsidiaries	—	—
Cash received from borrowings	8,265,727,336.78	6,162,238,486.31
Cash received relating to other financing activities	—	—
Sub-total of cash inflow from financing activities	8,282,155,280.66	6,220,542,405.15
Cash repayments of borrowings	6,957,913,214.43	5,396,980,526.12
Cash payments for distribution of dividends, profits or interest expenses	3,049,740,937.38	2,733,548,830.21
Including: Dividends and profits paid by subsidiaries to non-controlling shareholders	—	—
Cash paid relating to other financing activities	4,179,385,606.75	1,394,000,468.50
Sub-total of cash outflow from financing activities	14,187,039,758.56	9,524,529,824.83
Net cash flow generated from financing activities	-5,904,884,477.90	-3,303,987,419.68
<b>IV. Effect of fluctuations in exchange rates on cash and cash equivalents</b>	-9,427,113.53	231,612,284.73
<b>V. Net increase in cash and cash equivalents</b>	-729,436,079.41	1,462,447,448.32
Add: Balance of cash and cash equivalents at the beginning of the period	10,001,038,812.02	7,983,904,283.09
<b>VI. Balance of cash and cash equivalents at the end of the period</b>	9,271,602,732.61	9,446,351,731.41

Person in charge of the Company:	Ge Li
Chief Financial Officer:	Ming Shi
Director of the Accounting Department:	Jin Sun

### 3. Adjustments on the financial statements at the beginning of the first year of adopting new accounting standards or standard interpretations since 2024

Applicable     Not applicable

#### 4. Quarterly consolidated financial statements prepared in accordance with IFRSs

##### Consolidated Statement of Profit or Loss and Other Comprehensive Income January to September 2024

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000		Type of audit: Unaudited	
	Third quarter of 2024 (July – September)	Third quarter of 2023 (July – September)	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
<b>Revenue</b>	10,461,084	10,670,041	27,702,002	29,541,326
Cost of sales	<u>(6,063,813)</u>	<u>(6,154,250)</u>	<u>(16,603,841)</u>	<u>(17,469,850)</u>
<b>Gross profit</b>	<b><u>4,397,271</u></b>	<b><u>4,515,791</u></b>	<b><u>11,098,161</u></b>	<b><u>12,071,476</u></b>
Other income	247,625	182,861	758,642	622,662
Other gains and losses	(602,523)	14,896	(394,139)	1,076,049
Impairment losses under expected credit losses (“ECL”) model, net of reversal	(72,512)	(31,078)	(154,639)	(132,778)
Impairment losses of non-financial assets	—	—	—	(42,880)
Selling and marketing expenses	(189,060)	(167,746)	(546,582)	(521,220)
Administrative expenses	(687,388)	(732,540)	(1,964,873)	(2,059,022)
Research and development expenses	<u>(317,734)</u>	<u>(358,766)</u>	<u>(954,043)</u>	<u>(1,025,811)</u>
<b>Operating profit</b>	<b><u>2,775,679</u></b>	<b><u>3,423,418</u></b>	<b><u>7,842,527</u></b>	<b><u>9,988,476</u></b>
Share of results of associates	87,117	18,087	202,935	(58,387)
Share of results of joint ventures	184	(891)	(3,985)	6,804
Finance costs	<u>(58,237)</u>	<u>(53,861)</u>	<u>(187,180)</u>	<u>(154,927)</u>
<b>Profit before tax</b>	<b><u>2,804,743</u></b>	<b><u>3,386,753</u></b>	<b><u>7,854,297</u></b>	<b><u>9,781,966</u></b>
Income tax expense	<u>(483,977)</u>	<u>(595,002)</u>	<u>(1,252,685)</u>	<u>(1,633,319)</u>
<b>Profit for the period</b>	<b><u><u>2,320,766</u></u></b>	<b><u><u>2,791,751</u></u></b>	<b><u><u>6,601,612</u></u></b>	<b><u><u>8,148,647</u></u></b>

	Third quarter of 2024 (July – September)	Third quarter of 2023 (July – September)	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
<b>Other comprehensive (expense) income for the period</b>				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of financial statements of foreign operations	(429,330)	55,435	(161,808)	432,402
Fair value gain (loss) on hedging instrument designated in cash flow hedges	411,242	(85,702)	158,454	(976,337)
Other comprehensive expense for the period, net of income tax	(18,088)	(30,267)	(3,354)	(543,935)
<b>Total comprehensive income for the period</b>	<b><u>2,302,678</u></b>	<b><u>2,761,484</u></b>	<b><u>6,598,258</u></b>	<b><u>7,604,712</u></b>
<b>Profit for the period attributable to:</b>				
Owners of the Company	2,293,113	2,763,287	6,532,935	8,076,407
Non-controlling interests	27,653	28,464	68,677	72,240
	<b><u>2,320,766</u></b>	<b><u>2,791,751</u></b>	<b><u>6,601,612</u></b>	<b><u>8,148,647</u></b>
<b>Total comprehensive income for the period attributable to:</b>				
Owners of the Company	2,272,852	2,734,277	6,529,778	7,541,244
Non-controlling interests	29,826	27,207	68,480	63,468
	<b><u>2,302,678</u></b>	<b><u>2,761,484</u></b>	<b><u>6,598,258</u></b>	<b><u>7,604,712</u></b>
<b>Earnings per share (expressed in RMB per share)</b>				
— Basic	0.80	0.94	2.25	2.75
— Diluted	0.79	0.94	2.24	2.73



## Consolidated Statement of Financial Position

As at September 30, 2024

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000    Type of audit: Unaudited

	<b>As at September 30, 2024</b>	<b>As at December 31, 2023</b>
<b>Non-current Assets</b>		
Property, plant and equipment	26,006,848	25,844,429
Right-of-use assets	2,441,854	2,348,338
Goodwill	1,836,575	1,820,873
Other intangible assets	843,072	906,676
Interests in associates	2,345,576	2,180,396
Interests in joint ventures	24,597	35,234
Deferred tax assets	402,915	366,691
Financial assets at fair value through profit or loss (“FVTPL”)	8,660,660	8,626,009
Other non-current assets	116,675	105,755
Biological assets	1,096,719	1,012,478
	<b>43,775,491</b>	<b>43,246,879</b>
<b>Total Non-current Assets</b>		
<b>Current Assets</b>		
Inventories	3,470,767	2,886,094
Contract costs	903,290	695,583
Biological assets	973,735	1,154,553
Amounts due from related parties	68,583	86,702
Trade and other receivables	9,697,456	9,372,741
Contract assets	1,135,032	1,234,394
Income tax recoverable	61,450	17,526
Financial assets at FVTPL	—	11,003
Derivative financial instruments	100,895	414,035
Other current assets	—	785,780
Pledged bank deposits	1,602	1,610
Term deposits with initial term of over three months	4,778,336	3,761,410
Bank balances and cash	9,271,603	10,001,039
	<b>30,462,749</b>	<b>30,422,470</b>
<b>Total Current Assets</b>		
	<b>74,238,240</b>	<b>73,669,349</b>
<b>Total Assets</b>		

	As at September 30, 2024	As at December 31, 2023
<b>Current Liabilities</b>		
Trade and other payables	6,687,268	7,333,527
Amounts due to related parties	850	11,547
Derivative financial instruments	64,243	501,871
Contract liabilities	2,471,386	1,955,363
Bank borrowings	2,739,556	3,721,645
Lease liabilities	236,839	240,452
Income tax payables	727,279	991,891
	<hr/>	<hr/>
<b>Total Current Liabilities</b>	<b>12,927,421</b>	<b>14,756,296</b>
	<hr/>	<hr/>
<b>Non-current Liabilities</b>		
Bank borrowings	2,911,138	687,017
Deferred tax liabilities	593,915	530,107
Deferred income	1,019,989	1,079,932
Lease liabilities	1,202,535	1,098,552
	<hr/>	<hr/>
<b>Total Non-current Liabilities</b>	<b>5,727,577</b>	<b>3,395,608</b>
	<hr/>	<hr/>
<b>Total Liabilities</b>	<b>18,654,998</b>	<b>18,151,904</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>Capital and Reserves</b>		
Share capital	2,911,927	2,968,845
Reserves	52,261,621	52,153,609
	<hr/>	<hr/>
Equity attributable to owners of the Company	55,173,548	55,122,454
Non-controlling interests	409,694	394,991
	<hr/>	<hr/>
<b>Total Equity</b>	<b>55,583,242</b>	<b>55,517,445</b>
	<hr/> <hr/>	<hr/> <hr/>

## Consolidated Statement of Cash Flows

January to September 2024

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000    Type of audit: Unaudited

	<b>First three quarters of 2024 (January – September)</b>	<b>First three quarters of 2023 (January – September)</b>
<b>Net cash from operating activities</b>	<b>8,052,215</b>	<b>9,847,742</b>
<b>Investing activities</b>		
Interests received	381,651	328,799
Proceeds from disposal of financial assets at FVTPL	4,272,265	946,531
Purchases of financial assets at FVTPL	(4,238,584)	(3,566,779)
Withdrawal of certificates of deposits	700,000	500,000
Purchases of term deposits with initial term of over three months	(1,459,720)	—
Withdrawal of term deposit with initial term of over three months	362,825	—
Proceeds from disposal of a joint venture	6,301	—
Proceeds from disposal of other intangible assets	244	286
Proceeds from disposal of property, plant and equipment	9,490	10,786
Capital injection to an associate	(12,220)	—
Purchases of property, plant and equipment	(2,490,515)	(3,530,768)
Purchases of other intangible assets	(1,139)	(14)
Payments for right-of-use assets	—	(118,933)
Withdrawal (Payments) of rental deposits	719	(3,846)
Withdrawal (Placement) of pledged bank deposits	7	(373)
Net cash outflow on acquisition of subsidiaries	—	(22,092)
Dividends received from associates	—	8,754
Dividends received from financial assets at FVTPL	74,368	28,122
Payments on derivative financial instruments	(511,220)	(100,411)
R&D grants and others received related to assets	38,907	203,173
<b>Net cash used in investing activities</b>	<b>(2,866,621)</b>	<b>(5,316,765)</b>

	<b>First three quarters of 2024 (January – September)</b>	<b>First three quarters of 2023 (January – September)</b>
<b>Financing activities</b>		
Payments of dividends	(2,882,051)	(2,649,084)
New bank borrowings raised	8,265,727	6,162,239
Repayments of bank borrowings	(6,957,912)	(5,320,130)
Repayments of lease liabilities	(212,625)	(205,138)
Net proceeds from exercise of stock option	16,428	58,304
Payments on repurchase and cancellation of restricted A Shares	—	(425)
Interests paid	(167,690)	(84,465)
Acquisition of partial interest of subsidiaries from non-controlling shareholders	(58,570)	(2,806)
Payments on repurchase of A Shares and H Shares	(3,908,910)	(1,181,786)
Redemption of Convertible Bonds	—	(76,850)
	<u>(5,905,603)</u>	<u>(3,300,141)</u>
<b>Net cash used in financing activities</b>		
	<u>(5,905,603)</u>	<u>(3,300,141)</u>
<b>Net (decrease) increase in cash and cash equivalents</b>	<b>(720,009)</b>	<b>1,230,836</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>10,001,039</b>	<b>7,983,904</b>
Effects of exchange rate changes	(9,427)	231,612
	<u>10,001,039</u>	<u>7,983,904</u>
<b>Cash and cash equivalents at the end of the period</b>	<b><u>9,271,603</u></b>	<b><u>9,446,352</u></b>

## 5. Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company

	Unit: RMB million		Type of audit: Unaudited	
	Third quarter of 2024 (July – September)	Third quarter of 2023 (July – September)	First three quarters of 2024 (January – September)	First three quarters of 2023 (January – September)
<b>Net profit attributable to the owners of the Company</b>	<b>2,293.1</b>	<b>2,763.3</b>	<b>6,532.9</b>	<b>8,076.4</b>
Add:				
Share-based compensation expenses	79.4	156.2	244.4	480.6
Issuance expenses of Convertible Bonds	—	—	—	0.3
Fair value gain from derivative component of Convertible Bonds	—	—	—	(40.2)
Foreign exchange related losses (gains)	629.8	(18.3)	658.7	(354.8)
Amortization of acquired intangible assets from merge and acquisition	13.3	14.8	40.3	43.3
Non-financial assets impairment	—	—	—	42.9
<b>Non-IFRS net profit attributable to the owners of the Company</b>	<b><u>3,015.6</u></b>	<b><u>2,916.0</u></b>	<b><u>7,476.3</u></b>	<b><u>8,248.5</u></b>
Add:				
Realized and unrealized (gains) losses from venture capital investments	(41.9)	155.6	(134.6)	(74.6)
Realized and unrealized share of (gains) losses from joint ventures	(0.2)	0.9	4.0	(6.8)
<b>Adjusted non-IFRS net profit attributable to the owners of the Company</b>	<b><u>2,973.5</u></b>	<b><u>3,072.4</u></b>	<b><u>7,345.7</u></b>	<b><u>8,167.1</u></b>

*Note:* Any discrepancies between the total shown and the sum of the amounts listed in the above table are due to rounding.